Related Experiment Video
Updated: Jan 9, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Cardiovascular-Kidney-Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology
Aaron S Devanathan1, Thomas D Nolin1
1Department of Pharmacy & Therapeutics, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract:
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular-Kidney-Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART-associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby heightening the risk of drug-drug interactions and adverse drug effects. Therefore, CKM in PWH represents an emerging clinical pharmacology priority. We outline gaps and challenges and call for CKM research in PWH.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations

